Background
==========

Biologically complex diseases such as cancer are caused by mutations in biological pathways or functional groups instead of individual genes. Statistically, genes sharing the same pathway have high correlations and form functional groups or biological pathways. Many databases about biological knowledge or pathway information are available in the public domain after many years of intensive biomedical research. Such databases are often named metadata, which means data about data. Examples of such databases include the gene ontology (GO) databases (Gene Ontology Consortium, 2001), the Kyoto Encyclopedia of Genes and Genomes (KEGG) database \[[@B2]\], and several other pathways on the internet (e.g., <http://www.superarray.com>; <http://www.biocarta.com>). Most current methods, however, are developed purely from computational points without utilizing any prior biological knowledge or information. Gene selections with survival outcome data in the statistical literature are mainly within the penalized Cox or additive risk regression framework \[[@B3]-[@B8]\]. The *L*~1~and *L~p~*(*p*\< 1) penalized Cox regressions can work for simultaneous individual gene selection and survival prediction and have been extensively studied in statistics and bioinformatics literature \[[@B8]-[@B11]\]. The performance of the survival model is evaluated by the global area under the ROC curve summary (GAUCS) \[[@B12]\]. Unfortunately, those methods are mainly for individual gene selections and cannot be used to identify pathways directly. In microarray analysis, several popular tools for pathway analysis, including GENMAP, CHIPINFO, and GOMINER, are used to identify pathways that are over-expressed by differentially expressed genes. These gene set enrichment analysis (GSEA)methods are very informative and are potentially useful for identifying pathways that related to disease status \[[@B13]\]. One drawback with GSEA is that it considers each pathway separately and the pathway information is not utilized in the modeling stage. Wei and Li \[[@B14]\] proposed a boosting algorithm incorporating related pathway information for classification and regression. However, their method can only be applied for binary phenotypes. Since most complex diseases such as cancer are believed to be associated with the activities of multiple pathways, new statistical methods are required to select multiple pathways simultaneously with the time-to-event phenotypes.

A ROC curve provides complete information on the set of all possible combinations of true-positive and false-positive rates, but is also more generally useful as a graphic characterization of the magnitude of separation between the case and control distributions. AUC is known to measure the probability that the marker value (score) for a randomly selected case exceeds the marker value for a randomly selected control and is directly related to the Mann-Whitney U statistic \[[@B15],[@B16]\]. In survival analysis, a survival time can be viewed as a time-varying binary outcome. Given a fixed time t, the instances for which *t~i~*= *t*are regarded as cases and samples with *t~i~*\>*t*are controls. The global AUC summary (GAUCS) is then defined as *GAUCS*= *P*(*M~j~*\>*M~k~*\|*t~j~*\<*t~k~*), which indicates that subject who died at an earlier time has a larger score value, where *M*is a score function. Heagerty and Zheng \[[@B12]\] have shown that GAUCS is a weighted average of the area under time-specific ROC curves. Liu et al. \[[@B17]\] proposed a *L*~1~penalized quadratic support vector machine (SVM) method for GAUCS maximization and individual gene selection with survival outcomes and showed the method outperformed the Cox regression. However, that method is only for gene selections and can not be directly used for identifying pathways without additional criteria. Group LASSO (*L*~1~) related penalized methods have been extensively studied recently in logistic regression \[[@B18]\], multiple kernel learning \[[@B19]\], and microarray analysis \[[@B20]\] with binary phenotypes. The methods are designed for selecting groups of variables and identifying important covariate groups (pathways). However, LASSO is biased. *L~p~*(*p*≤ 1) (with one specific implementation entitled adaptive LASSO \[[@B1],[@B21]\]) is asymptotic unbiased and has oracle properties. Therefore, it is reasonable to extend the *L~p~*to group *L~p~*for pathway identifications. In this paper, we therefore extend *L~p~*to group *L~p~*penalty and develop a novel iterative gradient based algorithm for GAUCS maximization (IGGAUCS), which can effectively integrate genomic data and biological pathway information and identify disease associated pathways with right censored survival data. In Section 2, we formulate the GAUCS maximization and group *L~p~*penalty model and propose an efficient EM algorithm for survival prediction. Its performance is compared with its group lasso penalized Cox regression (implemented by ourselves). We also propose an integrated algorithm with GAUCS for microarray data analysis. The proposed approach is demonstrated with simulation and gene expression examples in Section 3. Concluding remarks are discussed in Section 4.

Group *L~p~*Penalized GAUCS Maximization
----------------------------------------

Consider we have a set of *n*independent observations $\left\{ t_{i},\delta_{i},\mathbf{\text{x}}_{i} \right\}_{i = 1}^{n}$, where *δ~i~*is the censoring indicator and *t~i~*is the survival time (event time) if *δ~i~*= 1 or censoring time if *δ~i~*= 0, and **x***~i~*is the *m*-dimensional input vector of the *i*th sample. We denote $N_{i}^{*}(t) = 1_{(t_{i} \leq t)}$ and the corresponding increment $dN_{i}^{*}(t) = N_{i}^{*}(t) - N_{i}^{*}(t - )$. The time-dependent sensitivity and specificity are defined by sensitivity (*c, t*): $\left. \text{Pr}(M_{i} > c \middle| t_{i} = t) = \text{Pr}(M_{i} > c \middle| dN_{i}^{*}(t)\, = 1) \right.$ and specificity (*c, t*): $\left. (\text{Pr}(M_{i} \leq c \middle| t_{i} > t) = \text{Pr}(M_{i} \leq c \middle| N_{i}^{*}(t) = 0) \right.$. Here sensitivity measures the expected fraction of subjects with a marker greater than *c*among the subpopulation of individuals who die (cases) at time *t*, while specificity measures the fraction of subjects with a marker less than or equal to *c*among those who survive (controls) beyond time *t*. With this definition, a subject can play the role of a control for an early time, *t*\<*t~i~*, but then play the role of case when *t*= *t~i~*. Then, ROC curves are defined as *ROC~t~*(*q*) = *TP~t~*{\[*FP~t~*\]^-1^(*q*)} for *q*ϵ \[0, 1\], and the area under the ROC curve for time *t*is $AUC\left( t \right)\,\, = \,\,{\int_{0}^{1}{ROC_{t}(q)dq}}$, where *TP~t~*and *FP~t~*are the true and false positive rate at time *t*respectively, and \[*FP*~*t*~\]^-1^(*q*) = inf~*c*~{*c*: *FP~t~*(*c*) ≤ *q*}. ROC methods can be used to characterize the ability of a marker to distinguish cases at time *t*from controls at time *t*. However, in many applications there is no prior time *t*identified and thus a global accuracy summary is defined by averaging over *t*:

$$\begin{matrix}
{GAUCS\, = \, 2\int AUC(t)g(t)S(t)dt} \\
\left. = \text{Pr}(M_{j} > M_{k} \middle| t_{j} < t_{k}), \right. \\
\end{matrix}$$

which indicates the probability that the subject who died (cases) at the early time has a larger value of the marker, where *S*(*t*) and g(*t*) are the survival and corresponding density functions, respectively.

Assuming there are *r*clusters in the input covariates, our primary aim is to identify a small number of clusters associated with survival time *t~i~*. Mathematically, for each input **x***~i~*ϵ ℝ*^m^*, we are given a decomposition of ℝ*^m^*as a product of *r*clusters:

${\mathbb{R}}^{m} = {\mathbb{R}}^{m_{1}} \times ... \times {\mathbb{R}}^{m_{r}}$, so that each data point **x***~i~*can be decomposed into *r*cluster components, i.e. **x***~i~*= (**x**~*i*1~,\...,**x***~ir~*), where each **x***~il~*is in general a vector. We define *M*(**x**) = **w***^T^***x**to be the risk score function, where $\mathbf{\text{w}} = {(\mathbf{\text{w}}_{1},\mathbf{\text{w}}_{2},...,\mathbf{\text{w}}_{r})}^{T} \in {\mathbb{R}}^{m_{1} + ,..., + m_{r}}$ is the vector of coefficients that has the same cluster decomposition as **x***~i~*. We denote *M~i~*= *M*(**x***~i~*) for simplicity. Our goal is to encourage the sparsity of vector **w**at the level of clusters; in particular, we want most of its multivariate components **w***~l~*to be zero. The natural way to achieve this is to explore the combination of *L~p~*(0 ≤ *p*≤ 1) norm and *L*~2~norm. Since **w**is defined by clusters, we define a weighted group *L~p~*norm

$$\left. L_{p} = {\sum\limits_{l = 1}^{r}d_{l}} \middle| \mathbf{\text{w}}_{l} \middle| {}_{p}, \right.$$

where within every group, an *L*~2~norm is used $\left. ( \middle| \mathbf{\text{w}}_{l} \middle| = {(\mathbf{\text{w}}_{l}^{T}\mathbf{\text{w}}_{l})}^{1/2}) \right.$ and *d~l~*can be set to be 1 if all clusters are equally important. Note that group *L~p~*= *L*~2~if *r*= 1 and *d~l~*= 1, and group *L~p~*= *L~p~*when *r*= *m*and *d~l~*= 1. We can define the optimization problem

$$\begin{array}{l}
\left. \max\, GAUCS\, = \,\max Pr(M_{j} > M_{k} \middle| t_{j} < t_{k}) \right. \\
{\text{s}.\text{t}.\,\,\,\,\,\,\,\,\,\,\,\,\,\,\, L_{p} < \beta,} \\
\end{array}$$

where *M~j~*= **w***^T^***x***~j~*. The ideal situation is that *M*(**x***~j~*) \>*M*(**x***~k~*) or **w***^T^*(**x***~j~*- **x***~k~*) \> 0, ∀ couple (**x***~j~*, **x***~k~*) with corresponding times *t~j~*\<*t~k~*(or *j*\<*k*) and *δ~j~*= 1.

*Pr*(*M~j~*\>*M~k~\|t~j~*\<*t~k~*) can be estimated as

$$\begin{matrix}
\left. GAUCS\, = \, Pr(M_{j} > M_{k} \middle| t_{j} < t_{k}) \right. \\
{= \frac{\sum_{\begin{array}{l}
{j < k} \\
{\delta_{j} = 1} \\
\end{array}}{\sum_{k = 2}^{n}\mathbf{1}_{M_{j} > M_{k}}}}{\sum_{\begin{array}{l}
{j < k} \\
{\delta_{j} = 1} \\
\end{array}}{\sum_{k = 2}^{n}1}},} \\
\end{matrix}$$

where **1**~a\>b~= 1 if *a*\>*b*, and 0 otherwise. Obviously, GAUCS is a measure to rank the patients\' survival time. The perfect *GAUCS*= 1 indicates that the order of all patients\' survival time are predicted correctly and *GAUCS*= 0.5 indicates for a completely random choice.

One way to approximate step function $1_{M_{j} > M_{k}}$ is to use a sigmoid function $\sigma(z) = \frac{1}{1 + e^{- z}}$ and let $N = {\sum_{\begin{array}{l}
{j < k} \\
{\delta_{j} = 1} \\
\end{array}}{\sum_{k = 2}^{n}1}}$, then

$$GAUCS = \frac{\sum_{\begin{array}{l}
{j < k} \\
{\delta_{j} = 1} \\
\end{array}}{\sum_{k = 2}^{n}{\sigma(\mathbf{\text{w}}^{T}(\mathbf{\text{x}}_{j} - \mathbf{\text{x}}_{k}))}}}{N}.$$

Equation (4) is nonconvex function and can only be solved with the conjugate gradient method to find a local minimum. Based on the property that the arithmetic average is greater than the geometric average, we have

$$\frac{\sum_{\begin{array}{l}
{j < k} \\
{\delta_{j} = 1} \\
\end{array}}{\sum_{k = 2}^{n}{\sigma(\mathbf{\text{w}}^{T}(\mathbf{\text{x}}_{j} - \mathbf{\text{x}}_{k}))}}}{N} \geq \frac{1}{N}{\prod\limits_{\begin{array}{l}
{j < k} \\
{\delta_{j} = 1} \\
\end{array}}{\prod\limits_{k = 2}^{n}{\sigma(\mathbf{\text{w}}^{T}(\mathbf{\text{x}}_{j} - \mathbf{\text{x}}_{k}))}}}.$$

We can, therefore, maximize the following log likelihood lower bound of equation (4).

$$\begin{matrix}
{E_{p}\, = \,\frac{1}{N}{\sum\limits_{\begin{array}{l}
{j < k} \\
{\delta j = 1} \\
\end{array}}{\sum\limits_{k = 2}^{n}{\log\sigma(\mathbf{\text{w}}^{T}(\mathbf{\text{x}}_{j} - \mathbf{\text{x}}_{k})) - \lambda L_{p}}}}} \\
{= \frac{1}{N}\,{\sum\limits_{\begin{array}{l}
{j < k} \\
{\delta j = 1} \\
\end{array}}{\sum\limits_{k = 2}^{n}{\log\,\sigma(\mathbf{\text{w}}^{T}(\mathbf{\text{x}}_{j} - \mathbf{\text{x}}_{k})) - \lambda}}}{\sum\limits_{l = 1}^{r}\left. d_{l} \middle| \mathbf{\text{w}}_{l} \right|^{p}},} \\
\end{matrix}$$

where λ is a penalized parameter controlling model complexity. Equation (5) is the maximum a posterior (MAP) estimator of **w**with Laplace prior provided we treat the sigmoid function as the pair-wise probability, i.e. *Pr*(*M~j~\> M~k~*) = σ(**w***^T^*(**x***~j~*- **x***~k~*)). When *p*= 1, *E~p~*is a convex function. A global optimal solution is guaranteed.

The IGGAUCS Algorithm
---------------------

In order to find the **w**that maximizes *E~p~*, we need to find the first order derivative. Since group *L~p~*with *p*≤ 1 is not differentiable at \|**w***~l~*\| = 0, differentiable approximations of group *L~p~*is required. We propose a local quadratic approximation for group \|**w***~l~*\|*^p^*based on convex duality and local variational methods \[[@B23],[@B24]\]. Fan and Li \[[@B25]\] proposed a similar approximation for single variable. The adaptive LASSO approach proposed by Zou and Li \[[@B21]\] is a LASSO (linear bound) approximation for *L~p~*penalty. The drawback with that approach is that LASSO itself is not differentiable at \|**w***~l~*\| = 0. Since \|**w***~l~*\|*^p^*is concave when *p*\< 1, we can have

$$\begin{matrix}
\left. f(\mathbf{\text{w}}_{l})\, = \, \middle| \mathbf{\text{w}}_{l} \middle| {}_{p} = \min\limits_{\eta_{l}}\left\{ \eta_{l} \middle| \mathbf{\text{w}}_{l} \middle| {}_{2} - g(\eta_{l}) \right\} \right. \\
{g(\eta_{l}) = \min\limits_{|\theta_{l}|}\left\{ \eta_{l} \middle| \theta_{l} \middle| {}_{2} - f(\theta_{l}) \right\},} \\
\end{matrix}$$

where the function *g*(.) is the dual function of *f*(.) in variational analysis. Geometrically, *g*(*η~l~*) represents the amounts of vertical shift applied to *η~l~*\|**w***~l~*\|^2^to obtain a quadratic upper bound with precision parameter *η~l~*, that touches *f*(**w***~l~*). Taking the first order derivative for $\eta_{l}\theta_{l}^{2} - f(\theta_{l})$, the minimum occurs at a solution of stationary equation when *θ~l~*≠ 0,

$$\left. 2\eta_{l} \middle| \theta_{l} \middle| - f^{\prime}(\theta_{l}) = 0\,\,\,\Rightarrow\,\,\,\eta_{l} = \frac{f^{\prime}(\theta_{l})}{\left. 2 \middle| \theta_{l} \right|}, \right.$$

and *f\'*(*θ~l~*) = *p*\|*θ~l~*\|^*p*-1^. Substituting into *f*(**w***~l~*), we have the variational bound:

$$\begin{array}{l}
\left| \mathbf{\text{w}}_{l} \middle| {}_{p} \leq \frac{f^{\prime}(\theta_{l})}{2\theta_{l}}( \middle| \mathbf{\text{w}}_{l} \middle| {}_{2} - \middle| \theta_{l} \middle| {}_{2}) + f(\theta_{l}) \right. \\
{\,\,\,\,\,\,\,\,\,\, = \frac{1}{2}\left\{ p \middle| \theta_{l} \middle| {}_{p - 2} \middle| \mathbf{\text{w}}_{l} \middle| {}_{2} + (2 - p) \middle| \theta_{l} \middle| {}_{p} \right\},} \\
\end{array}$$

where *θ~l~*denote variational parameters. With the local quadratic bound, we have the following smooth lower bound.

$$\begin{matrix}
{E_{p}\, = \,\frac{1}{N}{\sum\limits_{\begin{array}{l}
{j < k} \\
{\delta j = 1} \\
\end{array}}{\sum\limits_{k = 2}^{n}{\log\sigma(\mathbf{\text{w}}^{T}(\mathbf{\text{x}}_{j} - \mathbf{\text{x}}_{k})) - \lambda}}}{\sum\limits_{l = 1}^{r}\left. d_{l} \middle| \mathbf{\text{w}}_{l} \right|^{p}}} \\
{\geq \frac{1}{N}{\sum\limits_{\begin{array}{l}
{j < k} \\
{\delta j = 1} \\
\end{array}}{\sum\limits_{k = 2}^{n}{\log\sigma(\mathbf{\text{w}}^{T}(\mathbf{\text{x}}_{j} - \mathbf{\text{x}}_{k}))}}}} \\
{- \lambda{\sum\limits_{l = 1}^{r}{\frac{d_{l}}{2}\left\{ p \middle| \theta_{l} \middle| {}_{p - 2} \middle| \mathbf{\text{w}}_{l} \middle| {}_{2} + (2 - p) \middle| \theta_{l} \middle| {}_{p} \right\}}}} \\
{= E(\mathbf{\text{w}},\theta).} \\
\end{matrix}$$

In equation (8), the lower bound *E*(**w**, *θ*) is differentiable w.r.t both **w**and *θ*. We therefore propose a EM algorithm to maximize *E*(**w**, *θ*) w.r.t **w**while keeping *θ*fixed and maximize *E*(**w**, *θ*) w.r.t the variational parameter *θ*to tighten the variational bound while keeping **w**fixed. Convergence to the local optimum is guaranteed. Since maximization w.r.t the variational parameters *0*= (\|*θ*~1~\|,\|*θ*~2~\|,\..., \|*θ~r~*\|), with **w**being fixed, can be solved with the stationary equation $\frac{\partial E(\mathbf{\text{w}},\theta)}{\left. \partial \middle| \theta_{l} \right|} = 0$ we have *θ~l~*= **w***~l~*, for *l*= 1, 2,\..., *r*.

Given *r*candidate pathways potentially associated with the survival time, *m~l~*survival associated genes with the expression of **x***~l~*on each pathway *l*(*l*= 1, 2,\..., *r*), and letting **w**= (**w**~1~, **w**~2~,\..., **w***~r~*)^*T*^be a vector of the corresponding coefficients and $g(\mathbf{\text{w}}) = \frac{\partial_{\mathbf{\text{w}}}E(\mathbf{\text{w}},\theta)}{\partial\mathbf{\text{w}}}$, we have the following iterative gradient algorithm for *E*(**w**, *θ*) maximization:

The IGGAUCS Algorithm
---------------------

Given *p*, λ, and *ϵ*= 10^-6^, initializing $\mathbf{\text{w}}^{1} = {(\mathbf{\text{w}}_{1}^{1},\mathbf{\text{w}}_{2}^{1},...,\mathbf{\text{w}}_{r}^{1})}^{T}$ randomly with nonzero $\mathbf{\text{w}}_{l}^{1},\, l = 1,...,\, r$, and set *θ*^1^= w^1^.

Update w with *θ*fixed:

**w**^*t*+1^= **w**^*t*^+ *α^t^d^t^*, where *t*: the number of iterations and *α^t^*: the step size, *d^t^*is updated with the conjugate gradient method:

*d^t^*= g(**w**^*t*^) + *u^t^d^t^*and $u^{t} = \frac{{\lbrack g(\mathbf{\text{w}}^{t}) - g(\mathbf{\text{w}}^{t - 1})\rbrack}^{T}g(\mathbf{\text{w}}^{t})}{g{(\mathbf{\text{w}}^{t - 1})}^{T}g(\mathbf{\text{w}}^{t - 1})}$.

Update θ with w fixed:

*θ*^*t*+1^= **w**^*t*+1^

Stop when \|**w**^*t*+1^- **w**^*t*^\| \<*ϵ*or maximal number of iterations exceeded.

Choice of Parameters
--------------------

There are two parameters *p*and λ in this method, which can be determined through 10-fold cross validation. One efficient way is to set *p*= 0.1, 0.2,\..., and 1 respectively, and search for an optimal λ for each *p*using cross validation. The best (*p*, λ) pair will be found with the maximal test GAUCS value. Theoretically when *p*= 1, *E*(**w**, *θ*) is convex and we can find the global maximum easily, but the solution is biased and small values of p would lead to better asymptotic unbiased solutions. Our results with limited experiments show that optimal *p*usually happens at a small *p*such as *p*= 0.1. For comparison purposes, we implement the popular Cox regression with group LASSO (G*L*~1~Cox), since there is no software available in the literature. Our implementation is based on group LASSO penalized partial log-likelihood maximization. The best λ is searched from λ ϵ \[0.1, 25\] for IGGAUCS and from λ ϵ \[0.1, 40\] for G*L*~1~Cox method with the step size of 0.1, as the *L~p~*penalty goes to zero much quicker than *L*~1~. We suggest that the larger step size such as 0.5 can be used for most applications, since the test GAUCS does not change dramatically with a small change of λ.

Computational Results
=====================

Simulation Data
---------------

We first perform simulation studies to evaluate how well the IGGAUCS procedure performs when input data has a block structure. We focus on whether the important variable groups that are associated with survival outcomes can be selected using the IGGAUCS procedure and how well the model can be used for predicting the survival time for future patients. In our simulation studies, we simulate a data set with a sample size of 100 and 300 input variables with 100 groups (clusters). The triple variables **x**~1~- **x**~3~, **x**~4~- **x**~6~, **x**~7~- **x**~9~,\..., **x**~298~- **x**~300~within each group are highly correlated with a common correlation γ and there are no correlations between groups. We set γ = 0.1 for weak correlation, γ = 0.5 for moderate, and γ = 0.9 for strong correlation in each triple group and generate training and test data sets of sample size 100 with each γ respectively from a normal distribution with the band correlation structure. We assume that the first three groups(9 covariates) (**x**~1~- **x**~3~, **x**~4~- **x**~6~, **x**~7~- **x**~9~) are associated with survival and the 9 covariates are set to be **w**= \[-2.9 2.1 2.4 1.6 -1.8 1.4 0.4 0.8 -0.5\]^*t*^. With this setting, 3 covariates in the first group have the strongest association (largest covariate values) with survival time and 3 covariates in group 3 have less association with survival time. The survival time is generated with *H*= 100 exp(-**w**^*T*^**x**+ *ε*) and the Weibull distribution, and the census time is generated from 0.8\*median(time) plus a random noise. Based on this setting, we would expect about 25% - 35% censoring. To compare the performance of IGGAUCS and G*L*~1~Cox, we build the model based on training data set and evaluate the model with the test data set. We repeat this procedure 100 times and use the time-independent GAUCS to assess the predictive performance.

We first compare the performance of IGGAUCS and G*L*~1~Cox methods with the frequency of each of these three groups being selected under two different correlation structures based on 100 replications. The results are in Table [1](#T1){ref-type="table"}. Table [1](#T1){ref-type="table"} shows that IGGAUCS with *p*= 0.1 outperforms the G*L*~1~Cox in that IGGAUCS can identify the true group structures more frequently under different inner group correlation structures. Its performance is much better than G*L*~1~Cox regression, when the inner correlation in a group is high (γ = 0.9) and the variables within a group have weak association with survival time.

###### 

Frequency of Three Survival Associated Groups Selected in 100 Replications

                 **IGGAUCS/*GL***~**1**~**Cox**             
  -------------- -------------------------------- --------- ---------
  *w*~1~= -2.9                                              
  *w*~2~= 2.1    100/100                          100/100   100/100
  *w*~3~= 2.4                                               
                                                            
  *w*~4~= 1.6                                               
  *w*~5~= -1.8   100/78                           100/84    100/96
  *w*~6~= 1.4                                               
                                                            
  *w*~7~= 0.4                                               
  *w*~8~= 0.8    47/2                             53/4      94/24
  *w*~9~= -0.5                                              

To compare more about the performance of IGGAUCS and G*L*~1~Cox in parameter estimation, we show the results for each parameter with different inner correlation structures (0.1, 0.5, 0.9) in Figure [1](#F1){ref-type="fig"}. For each parameter in Figure [1](#F1){ref-type="fig"}, the left bar represents the parameter estimated from G*L*~1~Cox, the middle bar is the true value of the parameter, and the right bar indicates parameter estimated from IGGAUCS. We observe that both the G*L*~1~Cox and IGGAUCS methods estimated the sign of the parameters correctly for the first two groups. However both methods can only estimate the sign of *w*~8~correctly in group 3 with smaller coefficients. Moreover, **ŵ**estimated from IGGAUCS is much closer to the true **w**than that from G*L*~1~Cox, especially when the covariates are larger. This indicates that the *L~p~*(*p*= 0.1) penalty is less biased than the *L*~1~penalty. The estimators of IGGAUCS are larger than that of G*L*~1~Cox with weak, moderate, and strong correlations. Finally, the test global AUC summaries (GAUCSs) of IGGAUCS and G*L*1Cox with 100 replications are shown in Table [2](#T2){ref-type="table"}. Table [2](#T2){ref-type="table"} shows that IGGAUCS performs better than G*L*~1~Cox regression. This is reasonable, since our method, unlike Cox regression which maximizes a partial log likelihood, directly maximizes the penalized GAUCS. One interesting result is that the test GAUCSs become smaller as the inner group correlation coefficient γ increases from 0.1 to 0.9. We also apply the gene harvesting method proposed by Hastie et al. (2001) and discussed by Segal (2006) \[[@B7],[@B26]\] to the simulation data, but don\'t show the results in Table [2](#T2){ref-type="table"}. The gene harvest method uses the average gene expression in each group (cluster) and ignore the variance among genes within the group. The prediction performances are poor with test GAUCS of 0.57 ± 0.02 and 0.65 ± 0.016 respectively, when the correlations among genes are weak (γ = 0.1) and moderate (γ = 0.5). Its performance is slightly better with the test GAUCS of 0.75 ± 0.024, when γ = 0.9, but this4 performance is still not as good as either IGGAUCS or *GL*~1~Cox. One explantation is that the group is more heterogeneous with weaker correlations among variables, and the average does not provide a meaningful summary. Moreover, we cannot identify the survival association of individual variables using gene harvesting.

###### 

Test GAUCS of Simulated Data *w*ith Different Correlation Structures

  Correlation   IGGAUCS         ***GL***~**1**~**Cox**
  ------------- --------------- ------------------------
  γ = 0.1       0.921(±0.023)   0.897(±0.031)
  γ = 0.5       0.889(±0.021)   0.871(±0.024)
  γ = 0.9       0.866(±0.017)   0.828(±0.025)

![**True and Estimated Parameters**. The true and estimated parameters with the simulation data are shown in Figure 2. The left bars represent each parameter estimated from *GL*~1~Cox, the middle bars are the true value of the parameter, and the right bars indicate parameters estimated form IGGAUCS.](1748-7188-5-30-1){#F1}

### Follicular Lymphoma (FL) Data

Follicular lymphoma is a common type of Non-Hodgkin Lymphoma (NHL). It is a slow growing lymphoma that arises from B-cells, a type of white blood cell. It is also called an \"indolent\" or \"low-grad\" lymphoma for its slow nature, both in terms of its behavior and how it looks under the microscope. A study was conducted to predict the survival probability of patients with gene expression profiles of tumors at diagnosis \[[@B27]\].

Fresh-frozen tumor biopsy specimens and clinical data were obtained from 191 untreated patients who had received a diagnosis of follicular lymphoma between 1974 and 2001. The median age of patients at diagnosis was 51 years (range 23 - 81) and the median follow up time was 6.6 years (range less than 1.0 - 28.2). The median follow up time among patients alive was 8.1 years. Four records with missing survival information were excluded from the analysis. Affymetrix U133A and U133B microarray gene chips were used to measure gene expression levels from RNA samples. A log 2 transformation was applied to the Affymetrix measurement. Detailed experimental protocol can be found in Dave et al. 2004. The data set was normalized for each gene to have mean 0 and variance 1. Because the data is very large and there are many genes with their expressions that either do not change cross samples or change randomly, we filter out the genes by defining a correlation measure with GAUCS for each gene **x**~i~*R*(*t*, **x***~i~*) = \|2*GAUCS*(*t*, **x***~i~*) - 1\|, where *R*= 1 when *GAUCS*= 0, or 1 and *R*= 0 when *GAUCS*= 0.5 (gene **x***~i~*is not associated with the survival time). We perform the permutation test 1000 times for *R*to identify 2150 probes associated with survival time. We then identify 49 candidate pathways with 5 and more genes using DAVID. There are total 523 genes on the candidate pathways. Since a gene can be involved in more than one pathway, the number of distinguished genes should be a little less than 500. The 49 biological pathways are given in Table [3](#T3){ref-type="table"}. We finally apply IGGAUCS to identify the small number of biological pathways associated with survival phenotypes. We first randomly divide the data into two subsets, one for training with 137 samples, and the other for testing with 50 samples. To avoid overfitting and bias from a particular partition, we randomly partition the data 50 times to estimate the performance of the model with the average of the test GAUCS. The regularization parameter λ is tuned using 10-fold cross-validation with training data only.

###### 

Candidate Survival Associated Pathways

  Pathways                                     \# of Genes   Pathways                     \# of Genes
  -------------------------------------------- ------------- ---------------------------- -------------
  Propanoate metabolism                        5             Melanoma                     10
  Type II diabetes mellitus                    6             Thyroid cancer               5
  Adipocytokine signaling pathway              10            Prostate cancer              13
  Melanogenesis                                13            Glycolysis/Gluconeogenesis   8
  GnRH signaling pathway                       11            Butanoate metabolism         6
  Insulin signaling pathway                    15            Endometrial cancer           11
  Sphingolipid metabolism                      5             Pancreatic cancer            10
  Glycerophospholipid metabolism               9             Colorectal cancer            12
  T cell receptor signaling pathway            11            RNA polymerase               6
  Hematopoietic cell lineage                   10            Huntington\'s disease        5
  Glycerolipid metabolism                      6             Focal adhesion               20
  Toll-like receptor signaling pathway         13            Apoptosis                    12
  Antigen processing and presentation          9             Adherens junction            10
  Complement and coagulation cascades          8             Tryptophan metabolism        7
  ECM-receptor interaction                     14            Histidine metabolism         6
  Wnt signaling pathway                        20            Fatty acid metabolism        10
  Ubiquitin mediated proteolysis               15            Acute myeloid leukemia       9
  Neuroactive ligand-receptor interaction      28            Bladder cancer               6
  gamma-Hexachlorocyclohexane degradation      5             Focal adhesion               20
  Calcium signaling pathway                    21            ErbB signaling pathway       11
  MAPK signaling pathway                       31            PPAR signaling pathway       16
  Valine, leucine and isoleucine degradation   6             Glioma                       7
  Pyrimidine metabolism                        12            Chronic myeloid leukemia     10
  Glycan structures - degradation              5             Non-small cell lung cancer   11
  Porphyrin and chlorophyll metabolism         7                                          

Since it is possible different pathways may be selected in the cross validation procedure, the relevance count concept \[[@B28]\] was utilized to count how many times a pathway is selected in the cross validation. Clearly, the maximum relevance count for a pathway is 200 with the 10-fold cross validation and 20 repeating. We have selected 8 survival associated pathways with IGGAUCS. The average test GAUCS is 0.892 ± 0.013. Moreover, the parameters (weights) **w***~i~*and corresponding genes on each pathway indicate the association strength and direction between genes and the survival time. Positive *w~i~*s indicate that patients with high expression level die earlier and negative *w~i~*s represent that patients live longer with relatively high expression levels. The absolute values of \|*w~i~*\| indicate the strength of association between survival time and the specific gene. Genes on the pathway, estimated parameters, and relevance accounts are given in Table [4](#T4){ref-type="table"}.

###### 

Genes on pathway, relevance accounts, and estimated parameters

  *w~i~*                                                                GeneID     Gene Name
  --------------------------------------------------------------------- ---------- ----------------------------------------------------------------------------
  **ECM-receptor interaction (relevance counts: 200)**                             
                                                                                   
  0.2239                                                                CD36       cd36 antigen (collagen type i receptor, thrombospondin receptor)
  0.0409                                                                FNDC1      fibronectin type iii domain containing 1
  0.0746                                                                SV2C       synaptic vesicle glycoprotein 2c
  0.0804                                                                SDC1       syndecan 1
  -0.1255                                                               FN1        fibronectin 1
  0.0211                                                                LAMC1      laminin, gamma 1 (formerly lamb2)
  -0.0854                                                               GP5        glycoprotein v (platelet)
  -0.1130                                                               CD47       cd47 antigen (rh-related antigen, integrin-associated signal transducer)
  -0.1296                                                               THBS2      thrombospondin 2
  -0.0547                                                               COL1A2     collagen, type i, alpha 2
  -0.1024                                                               COL5A2     collagen, type v, alpha 2
  0.0861                                                                LAMB4      laminin, beta 4
  -0.0315                                                               COL1A1     collagen, type i, alpha 1
  0.0395                                                                AGRN       agrin RG
                                                                                   
  **Focal adhesion (relevance counts 145)**                                        
                                                                                   
  0.0054                                                                PAK3       p21 (cdkn1a)-activated kinase 3
  0.0446                                                                PIK3R3     phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma)
  0.0044                                                                PDPK1      3-phosphoinositide dependent protein kinase-1
  -0.0045                                                               BAD        bcl2-antagonist of cell death
  0.0087                                                                PARVA      parvin, alpha
  -0.0144                                                               FN1        fibronectin 1
  0.0041                                                                LAMC1      laminin, gamma 1 (formerly lamb2)
  -0.0202                                                               PARVG      parvin, gamma
  -0.0158                                                               THBS2      thrombospondin 2
  0.0134                                                                PPP1R12A   protein phosphatase 1, regulatory (inhibitor) subunit 12a
  -0.0044                                                               SOS1       son of sevenless homolog 1 (drosophila)
  -0.0084                                                               COL1A2     collagen, type i, alpha 2
  -0.0122                                                               COL5A2     collagen, type v, alpha 2
  0.0091                                                                LAMB4      laminin, beta 4 RG Homo sapiens
  -0.0068                                                               RAF1       v-raf-1 murine leukemia viral oncogene homolog 1
  -0.0038                                                               ACTN1      actinin, alpha 1
  -0.0034                                                               COL1A1     collagen, type i, alpha 1
  -0.0067                                                               GSK3B      glycogen synthase kinase 3 beta
  -0.0065                                                               MAPK8      mitogen-activated protein kinase 8
  -0.0030                                                               MYL7       myosin, light polypeptide 7, regulatory
                                                                                   
  **Neuroactive ligand-receptor interaction (relevance counts: 200)**              
                                                                                   
  0.0894                                                                P2RY6      pyrimidinergic receptor p2y, g-protein coupled, 6
  -0.2753                                                               PTAFR      platelet-activating factor receptor
  0.1648                                                                GLRA3      glycine receptor, alpha 3
  0.0857                                                                FPRL1      formyl peptide receptor-like 1
  -0.1783                                                               EDNRA      endothelin receptor type a
  0.3233                                                                HRH4       histamine receptor h4
  0.2106                                                                GRM2       glutamate receptor, metabotropic 2
  -0.1112                                                               GRIN1      glutamate receptor, ionotropic, n-methyl d-aspartate 1
  -0.0220                                                               PTHR1      parathyroid hormone receptor 1
  0.0971                                                                OPRM1      opioid receptor, mu 1
  -0.4303                                                               CTSG       cathepsin g
  -0.0404                                                               P2RY8      purinergic receptor p2y, g-protein coupled, 8
  -0.0783                                                               BDKRB1     bradykinin receptor b1
  0.3247                                                                FSHR       follicle stimulating hormone receptor
  -0.1430                                                               ADRA1B     adrenergic, alpha-1b-, receptor
  0.1464                                                                C3AR1      complement component 3a receptor 1
  0.1120                                                                P2RX2      purinergic receptor p2x, ligand-gated ion channel, 2
  0.0311                                                                AVPR1B     arginine vasopressin receptor 1b
  0.2646                                                                FPR1       formyl peptide receptor 1
  0.2003                                                                GABRA5     gamma-aminobutyric acid (gaba) a receptor, alpha 5
  -0.0278                                                               PRLR       prolactin receptor
  -0.1070                                                               ADORA1     adenosine a1 receptor
  0.2652                                                                HTR7       5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)
  -0.0194                                                               GABRA4     gamma-aminobutyric acid (gaba) a receptor, alpha 4
  0.0145                                                                GHRHR      growth hormone releasing hormone receptor
  -0.3163                                                               MAS1       mas1 oncogene
  -0.0760                                                               PTGER3     prostaglandin e receptor 3 (subtype ep3)
  0.2196                                                                PARD3      par-3 partitioning defective 3 homolog (c. elegans)
                                                                                   
  **Ubiquitin mediated proteolysis (relevance counts: 200)**                       
                                                                                   
  0.0186                                                                UBE2B      ubiquitin-conjugating enzyme e2b (rad6 homolog)
  -0.0677                                                               CUL4A      cullin 4a
  0.0051                                                                PML        promyelocytic leukemia
  -0.1023                                                               UBE3B      ubiquitin protein ligase e3b
  -0.1581                                                               UBE3C      ubiquitin protein ligase e3c
  0.1390                                                                BTRC       beta-transducin repeat containing
  -0.0669                                                               HERC3      hect domain and rld 3
  0.00009                                                               RBX1       ring-box 1
  0.0011                                                                CUL5       cullin 5
  0.0267                                                                ANAPC4     anaphase promoting complex subunit 4
  -0.0253                                                               UBE2L3     ubiquitin-conjugating enzyme e2l 3
  0.0096                                                                KEAP1      kelch-like ech-associated protein 1
  -0.0267                                                               UBE2E1     ubiquitin-conjugating enzyme e2e 1 (ubc4/5 homolog, yeast)
  0.0116                                                                CBL        cas-br-m (murine) ecotropic retroviral transforming sequence
  0.0328                                                                BIRC6      baculoviral iap repeat-containing 6 (apollon)
                                                                                   
  **Porphyrin and chlorophyll metabolism (relevance counts: 185)**                 
                                                                                   
  0.0330                                                                BLVRA      biliverdin reductase a
  -0.0103                                                               FTH1       ferritin, heavy polypeptide 1
  0.0227                                                                ALAD       aminolevulinate, delta-, dehydratase
  0.1983                                                                HMOX1      heme oxygenase (decycling) 1
  0.0070                                                                UROS       uroporphyrinogen iii synthase (congenital erythropoietic porphyria)
  -0.1596                                                               GUSB       glucuronidase, beta
  0.0077                                                                UGT2B15    udp glucuronosyltransferase 2 family, polypeptide b15
                                                                                   
  **Calcium signaling pathway (relevance counts: 200)**                            
                                                                                   
  -0.0025                                                               BST1       bone marrow stromal cell antigen 1
  0.0003                                                                BDKRB1     bradykinin receptor b1
  -0.0016                                                               PTAFR      platelet-activating factor receptor
  -0.0002                                                               ADRA1B     adrenergic, alpha-1b-, receptor
  -0.0007                                                               PPP3CC     protein phosphatase 3 (formerly 2b), catalytic subunit, gamma isoform
  -0.0001                                                               ADCY7      adenylate cyclase 7
  0.0008                                                                GNA11      guanine nucleotide binding protein (g protein), alpha 11 (gq class)
  -0.0013                                                               AVPR1B     arginine vasopressin receptor 1b
  0.0014                                                                P2RX2      purinergic receptor p2x, ligand-gated ion channel, 2
  -0.0013                                                               CACNA1E    calcium channel, voltage-dependent, alpha 1e subunit
  0.0004                                                                EDNRA      endothelin receptor type a
  0.00009                                                               SLC8A1     solute carrier family 8 (sodium/calcium exchanger), member 1
  0.0006                                                                CACNA1B    calcium channel, voltage-dependent, l type, alpha 1b subunit
  -0.0013                                                               PLCD1      phospholipase c, delta 1
  -0.0029                                                               HTR7       5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)
  0.0014                                                                GRIN1      glutamate receptor, ionotropic, n-methyl d-aspartate 1
  0.0028                                                                CAMK2A     calcium/calmodulin-dependent protein kinase (cam kinase) ii alpha
  -0.0024                                                               CACNA1I    calcium channel, voltage-dependent, alpha 1i subunit
  -0.0002                                                               TNNC1      troponin c type 1 (slow)
  0.0009                                                                PTGER3     prostaglandin e receptor 3 (subtype ep3)
  0.0012                                                                CACNA1F    calcium channel, voltage-dependent, alpha 1f subunit
                                                                                   
  **Fatty acid metabolism (relevance counts: 192)**                                
                                                                                   
  0.0043                                                                ACSL3      acyl-coa synthetase long-chain family member 3
  0.0675                                                                ALDH2      aldehyde dehydrogenase 2 family (mitochondrial)
  -0.0491                                                               ACAT2      acetyl-coenzyme a acetyltransferase 2 (acetoacetyl coenzyme a thiolase)
  0.0120                                                                ALDH1B1    aldehyde dehydrogenase 1 family, member b1
  0.0597                                                                CYP4A11    cytochrome p450, family 4, subfamily a, polypeptide 11
  -0.1447                                                               ACADSB     acyl-coenzyme a dehydrogenase, short/branched chain
  0.0736                                                                CPT1A      carnitine palmitoyltransferase 1a (liver)
  0.1075                                                                CPT1B      carnitine palmitoyltransferase 1b (muscle)
  -0.0366                                                               ACADVL     acyl-coenzyme a dehydrogenase, very long chain
  0.2168                                                                ADH4       alcohol dehydrogenase 4 (class ii), pi polypeptide
                                                                                   
  **MAPK signaling pathway (relevance counts: 200)**                               
                                                                                   
  -0.1570                                                               PLA2G10    phospholipase a2, group x
  -0.2415                                                               MAPKAPK5   mitogen-activated protein kinase-activated protein kinase 5
  -0.1636                                                               IL1B       interleukin 1, beta
  -0.0651                                                               ZAK        sterile alpha motif and leucine zipper containing kinase azk
  0.0572                                                                PPP3CC     protein phosphatase 3 (formerly 2b), catalytic subunit, gamma isoform
  -0.0674                                                               MAP3K2     mitogen-activated protein kinase kinase kinase 2
  -0.1729                                                               JUND       jun d proto-oncogene
  -0.1718                                                               SOS1       son of sevenless homolog 1 (drosophila)
  0.1082                                                                FGF14      fibroblast growth factor 14
  0.3102                                                                PTPN5      protein tyrosine phosphatase, non-receptor type 5
  -0.3903                                                               CACNB1     calcium channel, voltage-dependent, beta 1 subunit
  0.2678                                                                MAP3K7     mitogen-activated protein kinase kinase kinase 7
  0.3176                                                                CACNG8     calcium channel, voltage-dependent, gamma subunit 8
  0.0893                                                                FGF19      fibroblast growth factor 19
  -0.0853                                                               RRAS2      related ras viral (r-ras) oncogene homolog 2
  0.0215                                                                NLK        nemo-like kinase
  0.0452                                                                MAP4K4     mitogen-activated protein kinase kinase kinase kinase 4
  0.1639                                                                CACNA1E    calcium channel, voltage-dependent, alpha 1e subunit
  -0.0290                                                               ARRB1      arrestin, beta 1
  -0.1169                                                               STK4       serine/threonine kinase 4
  0.1008                                                                CACNA1B    calcium channel, voltage-dependent, l type, alpha 1b subunit
  0.0839                                                                MOS        v-mos moloney murine sarcoma viral oncogene homolog
  -0.1244                                                               MEF2C      mads box transcription enhancer factor 2, polypeptide c
  0.1572                                                                RAF1       v-raf-1 murine leukemia viral oncogene homolog 1
  0.1757                                                                MAPK8IP1   mitogen-activated protein kinase 8 interacting protein 1
  0.2908                                                                IKBKB      inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase beta
  -0.3452                                                               CACNA1I    calcium channel, voltage-dependent, alpha 1i subunit
  -0.2473                                                               MAPK8      mitogen-activated protein kinase 8
  -0.2339                                                               CACNA1F    calcium channel, voltage-dependent, alpha 1f subunit
  0.0979                                                                CD14       cd14 antigen
  -0.1047                                                               MRAS       muscle ras oncogene homolog

The eight KEGG pathways identified play an important role in patient survivals and they can be ranked with the average \|*w~j~*\|:*∑~j~*\|*w~j~*\|/*L*, where *L*is the number of genes on a pathway as shown in Table [5](#T5){ref-type="table"}. The identified 8 KEGG pathways fall into three categories (i) signaling molecules and interaction including the MAPK signaling pathway, the Calcium signaling pathway, Focal adhesion, ECM-receptor interactions and neuroactive ligand-receptor interactions, (ii) metabolic pathways including Fatty acid metabolism and Porphyrin and chlorophyll metabolism, and (iii) nitric oxide and cell stress including Ubiquitin mediated proteolysis. These pathways are involved in different aspects of genetic functions and are vital for cancer patient survivals. We only discuss the MAPK signaling pathway but others can be analyzed in a similar fashion. The top-rank MAPK signaling pathway transduces a large variety of external signals, leading to a wide range of cellular responses, including growth, differentiation, inflammation, and apoptosis invasiveness and ability to induce neovascularization. MAPK signaling pathway has been linked to different cancers including follicular lymphoma \[[@B29]\]. The pathway and genes on pathways are given in Figure [2](#F2){ref-type="fig"}.

###### 

Pathway Ranks

  Pathway                                   ***∑***~***j***~**\|*w***~***j***~**\|/*L***   Rank
  ----------------------------------------- ---------------------------------------------- ------
  MAPK signaling pathway                    0.1614                                         1
  Neuroactive ligand-receptor interaction   0.1562                                         2
  ECM-receptor interaction                  0.0863                                         3
  Fatty acid metabolism                     0.0772                                         4
  Porphyrin and chlorophyll metabolism      0.0627                                         5
  Ubiquitin mediated proteolysis            0.0494                                         6
  Focal adhesion                            0.0100                                         7
  Calcium signaling pathway                 0.0012                                         8

![**MAPK Signaling Pathway**. MAPK signaling pathway and the associated genes. Genes in red are highly expressed in patients who died earlier and genes in yellow are highly expressed in patients who lived longer.](1748-7188-5-30-2){#F2}

Genes in red color are highly expressed in patients with aggressive FL and genes in yellow are highly expressed in the earlier stage of FL cancers. Many important cancer related genes are identified with our methods. For example, SOS1, one of the RAS genes (e.g., MIM 190020), encodes membrane-bound guanine nucleotide-binding proteins that function in the transduction of signals that control cell growth and differentiation. Binding of GTP activates RAS proteins, and subsequent hydrolysis of the bound GTP to GDP and phosphate inactivates signaling by these proteins. GTP binding can be catalyzed by guanine nucleotide exchange factors for RAS, and GTP hydrolysis can be accelerated by GTPase-activating proteins (GAPs). SOS1 plays a crucial role in the coupling of RTKs and also intracellular tyrosine kinases to RAS activation. The deregulation of receptor tyrosine kinases (RTKs) or intracellular tyrosine kinases coupled to RAS activation has been involved in the development of a number of tumors, such as those in breast cancer, ovarian cancer and leukemia. Another gene, IL1B, is one of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. IL1B, one form of IL1, is made mainly by one type of white blood cell, the macrophage, and helps another type of white blood cell, the lymphocyte, fight infections. It also helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. IL1B made in the laboratory is used as a biological response modifier to boost the immune system in cancer therapy.

As shown in Figure [2](#F2){ref-type="fig"}, the genes SOS1, IL1B, RAS, CACNB1, MEF2C, JUND, and MAPKAPK5 are highly expressed in patients who were diagnosed earlier and lived longer and the genes FGF14, PTPN5, MOS, RAF1, CD14 are highly expressed in patients who were diagnosed at more aggressive stages and died earlier, which may indicate that oncogenes such such SOS1, JUND, and RAS may initialize FL cancer and genes such as MOS, IKK, and CD14 may cause FL cancer to be more aggressive. There are several causal relations among the identified genes on MAPK. For instance, the down-expressed SOS and RAS cause the up-expressed RAF1 and MOS and the up-stream gene IL1 is coordinately expressed with CASP and the gene MST1/2.

Conclusions
===========

Since a large amount of biological information on various aspects of systems and pathways is available in public databases, we are able to utilize this information in modeling genomic data and identifying pathways and genes and their interactions that might be related to patient survival. In this study, we have developed a novel iterative gradient algorithm for group *L~p~*penalized global AUC summary (IGGAUCS) maximization methods for gene and pathway identification, and for survival prediction with right censored survival data and high dimensional gene expression profile. We have demonstrated the applications of the proposed method with both simulation and the FL cancer data set. Empirical studies have shown the proposed approach is able to identify a small number of pathways with nice prediction performance. Unlike traditional statistical models, the proposed method naturally incorporates biological pathways information and it is also different from the commonly used Gene Set Enrichment Analysis (GSEA) in that it simultaneously considers multiple pathways associated with survival phenotypes.

With comprehensive knowledge of pathways and mammalian biology, we can greatly reduce the hypothesis space. By knowing the pathway and the genes that belong to particular pathways, we can limit the number of genes and gene-gene interactions that need to be considered in modeling high dimensional microarray data. The proposed method can efficiently handle thousands of genes and hundreds of pathways as shown in our analysis of the FL cancer data set.

There are several directions for our future investigations. For instance, we may want to further investigate the sensitivity of the proposed methods to the misspecification of the pathway information and misspecification of the model. We may also extend our method to incorporate gene-gene interactions and gene (pathway)- environmental interactions.

Even though we have only applied our methods to gene expression data, it is straightforward to extend our methods to SNP, miRNA CGH, and other genomic data without much modification.
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